Apnimed, Inc. (APMD) Key Metrics
APMD valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $739.4M
- Enterprise value
- $844.2M
- P/E (TTM)
- 2.5
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 6.4
- Price / book
- 4.4
- EV / EBITDA
- 23.7
- Dividend yield
- —
- Beta
- —
APMD key metrics, 2024–2025
Fiscal year ended December 31, 2025 · U.S. dollarsAPMD returns How much profit the business earns on the capital it uses.
APMD per-share figures Results divided by the shares outstanding at year-end.
APMD financial health Debt, liquidity and how easily interest is covered.
APMD efficiency & capital use Working capital cycle and where the cash goes.
APMD returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
APMD debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
APMD key metrics
2024–2025| 2025 | 2024 | |
|---|---|---|
| Per share | ||
| Revenue per share | $0.97 | $0.20 |
| Earnings per share | −$0.02 | −$2.79 |
| Operating cash flow per share | −$1.95 | −$2.77 |
| Free cash flow per share | −$1.95 | −$2.77 |
| Cash per share | $1.05 | $1.72 |
| Book value per share | −$9.36 | −$6.24 |
| Tangible book value per share | −$9.36 | −$6.24 |
| Capex per share | $0.00 | $0.00 |
| Debt per share | $1.02 | — |
| Shares outstanding | 39.8M | 39.8M |
| Change in shares outstanding | 0.0% | — |
| Returns & profitability | ||
| Return on assets (ROA) | −1.0% | −101.9% |
| Return on tangible assets | −1.3% | −101.9% |
| Free cash flow margin | −202.3% | — |
| Financial health | ||
| Total debt | $40.6M | — |
| Cash & short-term investments | $41.9M | $68.3M |
| Net debt | −$1.2M | −$68.3M |
| Debt / assets | 0.56 | — |
| Current ratio | 0.41 | 1.73 |
| Quick ratio | 0.41 | 1.73 |
| Working capital | −$65.8M | $30.9M |
| Invested capital | −$374.0M | −$317.0M |
| Tangible asset value | −$372.8M | −$248.6M |
| Net current asset value | −$400.6M | −$284.6M |
| Graham net-net per share | −$10.12 | −$7.25 |
| Capital allocation | ||
| Capex / revenue | 0.0% | 0.9% |
| Capex / depreciation | 0.00 | 3.04 |
| Stock-based compensation / revenue | 10.2% | 37.8% |
| R&D / revenue | 161.4% | 1,215.4% |
| SG&A / revenue | 61.1% | 268.4% |
| Efficiency | ||
| Days sales outstanding | 9.8 | 50.8 |
| Days payables outstanding | 146.5 | 388.4 |
| Cash conversion cycle (days) | -136.6 | -337.6 |
| Receivables turnover | 37.09 | 7.19 |
| Payables turnover | 2.49 | 0.94 |
| Asset turnover | 0.42 | 0.07 |
| Average receivables | $1.0M | $1.1M |
| Average payables | $2.7M | $3.6M |
| Intangibles / total assets | 0.0% | 0.0% |
Computed from APMD's annual financial statements (latest annual report filed —) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
APMD valuation and financial ratios
Based on the latest twelve months, the trailing P/E is 2.5. It ended the year with $40.6 million of debt and $41.9 million in cash and short-term investments, a net cash position of $1.2 million.
See the APMD income statement, the APMD chart for price history, or the APMD stock overview for the latest quote and news.
APMD key metrics FAQ
What is Apnimed's P/E ratio?
Apnimed's trailing P/E ratio is 2.5 based on the last twelve months of earnings (as of October 17, 2026). At the end of fiscal 2025 it was —.
How much debt does Apnimed have?
Apnimed had total debt of $40.6 million at the end of fiscal 2025 and more cash than debt.
What is Apnimed's current ratio?
Apnimed's current ratio was 0.41 at the end of fiscal 2025: current assets were 0.41 times current liabilities.